HOME >> MEDICINE >> NEWS
Study finds Velcade major improvement over standard therapy for relapsed multiple myeloma patients

NEW ORLEANSEarly results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

The findings, which will be presented at the annual meeting of the American Society of Clinical Oncology (Sunday, June 6, 2 p.m. Room 283) were sufficiently striking that the trial was stopped early so that patients who had been randomly assigned to receive dexamethasone could switch to bortezomib.

The study, which involved 669 patients in 92 treatment centers around the world, was the first head-to-head comparison of bortezomib and dexamethasone in a Phase III trial of patients who had relapsed after treatment for multiple myeloma. (Phase III trials test new treatments against standard ones to determine which is safer and more effective.)

"This trial represents the largest, most broad-based assessment to date of bortezomib and dexamethasone in this group of patients," says the study's lead author, Paul Richardson, MD, of Dana-Farber. "The finding that bortezomib significantly lengthened the time to disease progression and improved survival when compared with dexamethasone, with a similar level of safety, is important confirmatory evidence of bortezomib's effectiveness for patients with relapsed multiple myeloma."

Multiple myeloma is a currently incurable cancer of the bone marrow that causes a plunge in the production of vital red and white blood cells. Although relatively rare, it is the second most common type of blood cancer and accounts for 11,000 deaths annually in the United States. It is the fourth fastest-growing cancer in terms of mortality and is among the top 10 causes of death among African Americans.

In the new stud
'"/>

Contact: Bill Schaller
janet_haley@dfci.harvard.edu
617-233-5507
Dana-Farber Cancer Institute
5-Jun-2004


Page: 1 2 3

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2018)... ... November 14, 2018 , ... ... the All-In-One Video Ecommerce Solution, to power its "Ask an Expert" online mentor ... in live 30 and 60-minute one-to-one virtual sessions that are focused on starting ...
(Date:11/14/2018)... ... November 14, 2018 , ... For what is a first time at ... for Eating Disorders, will present an overview of the EFFT model with a focus ... at the 2019 event. , Next year’s 33rd iaedp™ Symposium is slated for ...
(Date:11/14/2018)... Ind. (PRWEB) , ... November 14, 2018 , ... ... 25mm lengths to its FortiCore® rotatable Posterior Lumbar Interbody Fusion (PLIF) devices. , ... driven growth with the expansion of their FortiCore PLIF product line with the addition ...
(Date:11/13/2018)... ... 13, 2018 , ... A survey by the publishers of ADC Review ... antibody therapies reached U.S. $ 4 billion. Approximately forty-five percent of this market included ... therapies (including ADCs) is expected to grow significantly, to U.S. $ 17 billion by ...
(Date:11/13/2018)... CLAREMONT, Calif. (PRWEB) , ... November 13, 2018 ... ... Surgeon General called for increased awareness and use of naloxone, an opioid overdose ... trained pharmacists to provide naloxone to individuals without a prescription. , ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 15, 2018 , ... ... healthcare organizations, today announced a strategic partnership with Formativ Health, a technology-enabled, ... Connector will perform platform integrations that connect Formativ Health’s clients’ Healthcare IT ...
(Date:11/15/2018)... ... November 15, 2018 , ... Mobile exoskeleton ... estimated to continue its dominance during the study period. The segment growth is ... to the wearer while augmenting strength to lift heavy load. Stationary products are ...
(Date:11/15/2018)... ... November 15, 2018 , ... This exclusive ranking ... moving our economy forward. The award, known as the Omni500, represents the most ... of sustainable growth among the communities they serve.2018 marks OMNIKAL’S 18th annual listing ...
Breaking Medicine Technology:
Cached News: